Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments

British Journal of Cancer

Volumn 74, Issue 9, 1996, Pages 1397-1405

  Casey, J L ^a   King, D J ^b   Chaplin, L C ^b   Haines, A M R ^b   Pedley, R B ^a   Mountain, A ^b   Yarranton, G T ^b   Begent, R H J ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b UCB PHARMA   (Belgium)

Author keywords

Di Fab; Maleimide cross linking; Radioimmunotherapy; Tri Fab

Indexed keywords

ANTINEOPLASTIC AGENT; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IODINE 131; YTTRIUM 90;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BETA RADIATION; COLORECTAL TUMOR; CROSS LINKING; DRUG TARGETING; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; KIDNEY CLEARANCE; KINETICS; MOUSE; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RETICULOENDOTHELIAL SYSTEM; TUMOR XENOGRAFT;

EID: 0029851132     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.555     Document Type: Article

References (44)

1. ABRAHAM R, BUXBAUM S, LINK J, SMITH R, VENTI C AND DARSLEY M. (1995). Screening and kinetic analysis of recombinant anti-CEA antibody fragments. J. Immunol. Methods. 183, 119 125.
2. ADAIR JA, BODMER MW, MOUNTAIN A AND OWENS RJ (1992). CDR grafted anti-CEA antibodies and their production. World patient application. WO 92/01059.
3. 2 and Fab́ fragments by imaging tumour xenografts. Eur. J. Nucl. Med., 13, 598 604.
4. BEGENT RHJ AND PEDLEY RB. (1990). Antibody targeted therapy in cancer: comparison of murine and clinical studies. Cancer Treat. Rev., 17, 373 378.
5. BEGENT RHJ, BAGSHAWE KD, PEDLEY RB, SEARLE F, LEDERMANN JA, GREEN AJ, KEEP PA, CHESTER KA, GLASER MG AND DALE RG. (1987). Use of second antibody in radioimmunotherapy. NCI Monogr., 31, 1035 1044.
6. BOXER GM, BEGENT RHJ, KELLY AMB, SOUTHALL PJ, BLAIR SB, THEODOROU NA, DAWSON PM AND LEDERMANN JA. (1992). Factors influencing variability of localisation of antibodies to carcinoembryonic antigen (CEA) in patients with colorectal cancer implications for radioimmunotherapy. Br. J. Cancer, 65, 825 831.
7. 111In. Cancer Res., 47, 1149 1154.
8. 131I-labelled monoclonal anti-CEA antibodies in a nude mouse model. Int. J. Cancer, 41, 127 134.
9. 2 fragments are more effective and less toxic than intact anti-CEA antibodies in radioimmunotherapy of large human colon carcinoma grafted in nude mice. J. Nucl. Med., 31, 1035 1044.
10. 4 sub-class in vivo. Int. J. Cancer. 50, 416 422.
11. CARTER P, KELLEY RE, RODRIQUES ML, SNEDCOR B, COVARRUBIAS M, VELLIGAN MD, WONG WLT, ROWLAND AM, KOTTS CE, CARVER ME, YANG M, BOURELL JH, SHEPARD HM AND HENNER D. (1992). High level Escherichia coli expression and production of a bivalent humanised antibody fragment. Bio Technology, 10, 163 167.
12. CASEY JL, CHESTER KA, ROBSON L, HAWKINS, RE AND BEGENT RHJ. (1995). Purification of bacterially expressed single chain antibodies for clinical applications using metal chelate chromatography. J. Immunol. Methods, 179, 105 116.
13. CHESTER KA, BEGENT RHJ, ROBSON L, KEEP PA, PEDLEY RB, BODEN JA, BOXER GM, GREEN AJ, WINTER G, COCHET O AND HAWKINS RE. (1994). Phage libraries for the generation of clinically useful antibodies. Lancet, 343, 455 457.
14. 2. and Fab́ in mice. Cancer Res., 46, 3969 3978.
15. COX JP, JANKOWSKI KJ, KATAKY R, PARKER D, BEELEY NRA, BOYCE BA, EATON MAW, MILLAR K, MILLICAN AT, HARRISON A AND WALKER C. (1989). Synthesis of a kinetically stable yttrium-90 labelled macrocycle-antibody conjugate. J. Chem. Soc. Chem. Commun., 1989, 797 798.
16. CUMBER AJ, WARD ES, WINTER G, PERNELL GD AND WARWRZNCZAK EJ. (1992). Comparative stabilities in vitro and in vivo of a recombinant mouse antibody FvCys fragment and a bisFvCys conjugate. J. Immunol., 149, 120 126.
17. DELALOYE AB AND DELALOYE B. (1995). Radiolabelled monoclonal antibodies in tumour imaging and therapy: out of fashion? Eur. J. Nucl. Med., 22, 571 580.
18. 2 antibody containing thioether-linked Fab́γ fragments. J. Immunol., 7, 2367 2375.
19. 88Y-Janus-2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA) in BALB/c mice with KHJJ adenocarcinoma: a model for radioimmunotherapy. Cancer Res., 54, 5937 - 5946.
20. 90Y from cyclic and acyclic ligand-antibody conjugates. Nucl. Med. Biol., 18, 469 476.
21. HIRD V, VERHOEYEN M, BADLEY RA, PRICE D, SNOOK D, KOSMAS C, GOODEN C, BAMIAS A, MEARES CF, LAVENDER JP AND EPENETOS AA. (1991). Tumour localisation with a radioactivity labelled reshaped human monoclonal antibody. Br. J. Cancer, 64, 911 914.
22. HNATOWICH DJ, CHILDS RL, LANTEIGNE D AND NAJAFI A. (1983). The preparation of DTPA-coupled antibodies radiolabelled with metallic radionuclides: an improved method. J. Immunol. Methods, 65, 147 152.
23. JURCIC JG AND SCHEINBERG DA. (1994). Recent developments in the radioimmunotherapy of cancer. Curr. Opin. Immunol., 6, 715 - 721.
24. KING DJ, TURNER A, KARNSWORTH APH, ADAIR JR, OWENS RJ, PEDLEY RB, BALDOCK D, PROUDFOOT KA, LAWSON ADG, BEELEY NRA, MILLAR K, MILLICAN A, BOYCE BA, ANTONIW P, MOUNTAIN A, BEGENT RHJ, SHOCAT D AND YARRANTON GT. (1994). Improved tumour targeting with chemically cross-linked recombinant antibody fragments. Cancer Res., 54, 6176 6185.
25. KING DJ, ANTONIW P, OWENS RJ, ADAIR JR, HAINES AMR, FARNSWORTH APH, FINNEY H, LAWSON ADG, LYONS A, BAKER TS, BALDOCK D, MACKINTOSH J, GOFTON C, YARRANTON GT, MCWILLIAMS W, SHOCAT D, LEICHNER PK, WELT S, OLD LJ AND MOUNTAIN A. (1995). Preparation and preclinical evaluation of humanised A33 immunoconjugates for radioimmunotherapy. Br. J. Cancer, 72, 1364 - 1372.
26. 2 antibodies. Br. J. Cancer, 70, 521 525.
27. LARSON SM, DIVGI CR AND SCOTT AM. (1994). Overview of clinical radioimmunodetection of human tumours. Cancer, 73, 832 - 835.
28. MOI MK, MEARES CF AND DENARDO SJ. (1988). The peptide way to macrocycle bifunctional chelating agents: synthesis of 2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecane-N,N′,N″, N‴-tetraacetid acid, and study of its yttrium (III) complex. J. Am. Chem. Soc., 110, 6266 6267.
29. NORRGREN K, STRAND SE, NILSSON R, LINDGREN L AND SJOGREN HO. (1993). A general, extracorporeal method to increase the tumour to normal tissue ratio in radioimmunoimaging and radioimmunotherapy. J. Nucl. Med., 34, 448 - 454.
30. 131I anti-CEA antibody in a colonic xenograft model. Br. J. Cancer, 68, 69 - 73.
31. 2 and Fab fragments in nude mice with human tumour xenografts: implications for tumour imaging and radioimmunotherapy. Nucl. Med. Commun., 10, 585 593.
32. PRESS OW, DESANTES K, ANDERSON SK AND GEISSLER F. (1990). Inhibition of catabolism of radiolabelled antibodies by tumour cells using lysosomotrophic amines and carboxylic ionophores. Cancer Res., 50, 1243 - 1250.
33. 2 fragments of monoclonal antiferritin in nude mouse model. J. Nucl. Med., 34, 2152 - 2159.
34. SCHOTT ME, MILENIC DE, YOKOTA T, WHITLOW M, WOOD JF, FORDYCE WA, CHENG RC AND SCHLOM J. (1992). Differential metabolic patterns of iodinated versus radiometal chelated anticarcinoma single chain Fv molecules. Cancer Res., 52, 6413 - 6417.
35. SCHOTT ME, FRAZIER KA, POLLOCK DK AND VERBLANC M. (1993). Preparation, characterisation and in vivo biodistribution properties of synthetically cross-linked multivalent antitumour antibody fragments. Bioconj. Chem., 4, 153 - 165.
36. SHARKEY RM, MOTTA-HENNESSY C, PAWLYK D, SIEGAL JA AND GOLDENBERG DM. (1990). Biodistribution and radiation dose estimates for yttrium and iodine labelled monoclonal antibody fragments in nude mice bearing human colonic tumour xenografts. Cancer Res., 50, 2330 - 2336.
37. SUMPIO BE AND HAYSLETT JP. (1985). Renal handling of proteins in normal and disease states. Quart. J. Med., 57, 611 - 635.
38. TURNER A, KING DJ, FARNSWORTH APH, RHIND SK, PEDLEY RB, BODEN JA, BODEN R, MILLICAN TA, MILLAR K, BOYCE B, BEELEY NRA, EATON MAW AND PARKER D. (1994). Comparative biodistributions of indium-111-labelled macrocycle chimeric B72.3 antibody conjugates in tumour bearing mice. Br. J. Cancer, 70, 35 - 41.
39. 3 derivatives that use the cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cell. J. Immunol., 147, 60 - 69.
40. 99mTc radiolabelling using a phage derived single chain Fv with a C-terminal cysteine. J. Nucl. Med., 37, 5, 868 - 872.
41. WALDMANN TA. (1991). Monoclonal antibodies in diagnosis and therapy. Science, 252, 1657 - 1662.
42. WERLEN RC, LANKINEN M, OFFORD RE, SCHUBIGER PA, SMITH A AND ROSE K. (1996). Preparation of a trivalent antigen-binding construct using polyoxime chemistry: improved biodistribution and potential for therapeutic application. Cancer Res., 56, 809 - 815.
43. YOKOTA T, MILENIC DE, WHITLOW M AND SCHLOM J. (1992). Rapid tumour penetration of a single chain Fv and comparison with other immunoglubin forms. Cancer Res., 52, 3402 - 3408.
44. YORKE ED, BEAUMIER PL, WESSELS BW, FRITZBERG AR AND MORGAN JR. (1991). Optimal antibody-radionuclide combinations for clinical radioimmunotherapy: a predictive model based on mouse pharmacokinetics. Nucl. Med. Biol., 18, 827 - 835.